anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Dysmobility syndrome based on osteoporosis (ODS) is a disease characterized by low bone mass and low muscle mass. Its features are high fracture and high fall risk. Falls and fractures are the most important factors affecting the quality of life and lifespan of ODS. However, there is no serum marker for the evaluation of ODS patients.Our previous studies have shown that the expression of circulating miRNA is stable and is a good marker for disease diagnosis. Therefore, this study aims to explore potential serum markers of ODS.
METHODS: A total of 78 subjects were included in this study. The data including appendicular skeletal muscle mass index, bone mineral density, bone metabolism markers, and other relevant information were collected for analysis. Real-time quantitative polymerase chain reaction was used to detect 19 miRNAs associated with muscle mass reduction. The correlation of quantitative data was analyzed by Pearson. The receiver operating characteristic curve was used to evaluate the performance of miRNA as a biomarker.
RESULTS: In this study, we found that the muscle mass and strength of patients with ODS are significantly reduced and are negatively correlated with the risk of fracture. The hsa-miR-499a-5p is specifically downregulated in ODS, and is positively correlated with muscle mass and strength, and negatively correlated with the risk of fracture. Compared with muscle mass and strength, hsa-miR-499a-5p has better sensitivity and specificity as a diagnostic marker.
CONCLUSION: hsa-miR-499a-5p is a potential serum biomarker for assessing muscle function and predicting fall or fracture risk in the ODS population.
Systems and methods for complex care tools are disclosed. For example, user data associated with users that have benefited from enrollment in a complex care program may be utilized to predict additional users that are also likely to benefit from enrollment. The presently disclosed systems and methods may determine reductions in cost profiles associated with enrolled users that exceed a reduction value, where the reduction value indicates the intended benefit of the complex care program has been achieved. The system may then associate user data of such users with the reduction value. As such, the system may utilize this data to predict additional users that are likely to benefit from enrollment. In this way, the system may engage such users to promote enrollment so that care costs may be reduced.
BACKGROUND: This study aimed to investigate functions of GLP-1R agonist by liraglutide (LIRA) and revealing the mechanism related to AGEs/RAGE in chondrocytes.
METHODS: To illustrate potential effect of GLP-1R agonist on AGEs induced chondrocytes, chondrocytes were administrated by AGEs with LIRA and GLP-1R inhibitor exendin. Inflammatory factors were assessed using ELISA. Real-time PCR was used to evaluate the catabolic activity MMPs and ADAMTS mRNA level, as well as anabolic activity (aggrecan and collagen II). RAGE expression was investigated by Western blotting. TUNEL, caspase3 activity and immunofluorescence were performed to test the apoptotic activity.
RESULTS: Our results showed that treatment with LIRA at > 100 nM attenuated the AGE-induced chondrocyte viability. Western bolt demonstrated that GLP-1R activation by LIRA treatment reduced RAGE protein expression compared with the AGEs groups. ELISA showed that LIRA hindered the AGEs-induced production of inflammatory cytokines (IL-6, IL-12 and TNF-α) in primary chondrocytes. AGEs induced catabolism levels (MMP-1, -3, -13 and ADAMTS-4, 5) are also attenuated by LIRA, causing the retention of more extracellular matrix (Aggrecan and Collagen II). TUNEL, caspase3 activity and immunofluorescence results indicated that LIRA inhibited the AGEs-induced production of inflammatory cytokines in primary chondrocytes and attenuated the caspase 3 level, leading to the reduced apoptotic activity. All the protective effects are reversed by exendin (GLP-1R blockers).
CONCLUSIONS: The present study demonstrates for the first time that LIRA, an agonist for GLP-1R which is commonly used in type 2 diabetes reverses AGEs induced chondrocyte inflammation and apoptosis through suppressing RAGE signaling, contributing to reduced catabolism and retention of more extracellular matrix. The above results indicate the possible effect of GLP-1R agonist on treating OA.
1. Technical Result Reduce of side effects, increase in treatment efficiency. 2. Essence The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such compounds. 3. Field of Application Medicine. Tables: 2
INTRODUCTION: Typically, oncology is not a structured part of the curriculum in Brazilian medical schools. Furthermore, sarcomas, which are uncommon tumors, are seldom covered in depth. A lack of comprehensive education on sarcomas might result in medical professionals being ill-equipped to care for patients with this condition.
OBJECTIVES: To assess medical students' understanding and awareness of sarcomas and the specific principles related to these tumors.
MATERIALS AND METHODS: A quantitative, cross-sectional study was conducted using a questionnaire, applied to medical students, focusing on the epidemiology, pathophysiology, and treatments of bone and soft tissue sarcomas. In all tests, the significance level adopted was 5%. The SPSS version 25.0 software was used.
RESULTS: Of the 825 questionnaires distributed, 325 were returned. Educational sessions on sarcomas did not appear to significantly improve the student's knowledge. Only 29.5% of students identified the lack of pain as an indicator of potential malignancy in soft tissue sarcomas, while 73.8% correctly recognized pain as a symptom of bone sarcomas. Limb amputation as the optimal surgical method for patient recovery was incorrectly reported by 39.1% of the sample.
CONCLUSION: A great part of the surveyed population does not have adequate knowledge about the basic concepts associated with limb sarcomas. The minority of them are satisfied with the knowledge gained during their medical education about these tumors. Inadequate medical academic training may initially lead to the wrong clinical management of patients with bone and soft tissue tumor lesions. An educational effort is needed to enhance oncology education for medical students, especially concerning sarcomas.
The present invention relates to novel compounds and their use as medicaments, in particular for the treatment of proliferative disorders. The invention also relates to pharmaceutical compositions comprising the novel compounds. Furthermore, the present invention relates to methods of inhibiting proliferation or metastasis of cancer cells, or inducing cell death thereof, in an individual in need thereof. In addition, the present invention relates to methods of inhibiting proliferation of cell populations susceptible to inhibition of RAS activation, particularly KRAS, HRAS and NRAS activation, in vitro. Furthermore, the invention relates to methods of inhibiting proliferation of a population of cells susceptible to inhibition of the eIF4A complex in vitro. Furthermore, the invention relates to a kit comprising a formulation comprising a pharmaceutical composition comprising a compound according to the invention.
The present application provides novel compositions comprising posaconazole and a polymer wherein the composition has a glass transition temperature temperature (Tg) of less than about 1100C. The application also describes compositions comprising posaconazole and a polymer having a bulk density of greater than about 0.4 mg/mL. The application also describes compositions comprising posaconazole and a polymer which provide an exposure (AUCtf) of at least about 10,000 ng.hr/mL when administered to a patient in a fasted state. The application also describes a novel process for preparing these compositions. The preff erred polymer is HPMCAS. Preferably the composition is an extruded material.
Consecutive patients admitted for non coronary disease, will follow their clinical pathway. They will be classified into free from migraine (group 2, N=45) and will be enrolled in the study.
The investigators main goal is to confirm the safety of transcranial direct current stimulation (tDCS) associated with conventional physical therapy, compared to conventional physical therapy associated with sham tDCS, for upper limb rehabilitation in an early phase (72 hours until 6 weeks) after stroke. Patients will be randomized to receive one of these two treatments, 3 times per week, for 2 weeks. Adverse effects will be monitored during each session. The working hypothesis is that conventional physical therapy associated with active tDCS in the subacute phase of ischemic stroke will be as safe as conventional therapy alone. The investigators will also preliminarily evaluate the efficacy of active tDCS associated with conventional therapy, compared to conventional therapy alone, in improvement of upper limb motor impairment. The investigators secondary goals are: 1) To compare effects of the above mentioned interventions on disability, spasticity and quality of life, in patients at an early stage after stroke ( subacute phase), immediately after treatment and 3 months later. The investigators hypothesis is that the association of conventional physical therapy and active tDCS will lead to better outcomes than conventional therapy alone. Patients will be assessed before the first session and after the last session of treatment, as well as 3 months after the last session of treatment.

Preliminary data about structural and functional connectivity will be collected in order to plan future studies related to mechanisms of tDCS in the subacute phase after stroke.
PURPOSE: A pharmaceutical composition and a health functional food containing taro extract for enhancing immune system are provided to be used as a therapeutic agent for anticancer and anti-metastasis. CONSTITUTION: A pharmaceutical composition for enhancing immune system contains polymer saccharides of chemical formula 1 as an active ingredient. A health functional food for enhancing immune system contains the polymer saccharides as an active ingredient. A pharmaceutical composition for anti-metastasis contains the polymer polysaccharides of chemical formula 1 as an active ingredient. A pharmaceutical composition for enhancing immune system contains taro exract as an active ingredient. The taro extract contains galactose and mannose. A health functional food for enhancing immune system contains the taro extract as an active ingredient.
BACKGROUND: Hyperpigmented scars, particularly in exposed body areas, can be difficult to conceal and may evoke psychological distress. While the precise causes of scar dyschromia are not fully understood, alterations in melanogenic activity appear to hold more significance than changes in melanocyte quantity. Current treatments encompass laser interventions. However, it is essential to consider their costs and potential complications in relation to their limited proven effectiveness. Fat grafting has gained interest as a scar modulation technique due to its regenerative properties, and its efficacy in reducing scar hyperpigmentation is currently under investigation.
METHODS: A systematic review and meta-analysis was reported according to PRISMA guidelines. PubMed, Embase, and Cochrane Library databases were accessed. PROSPERO registration number is CRD42023457778. The primary outcome was a change in scar pigmentation after fat grafting. Pigmentation changes after fat grafting were calculated using the standardized mean difference (SMD) between baseline and postoperative scores according to POSAS and VSS scales. Bias assessment was conducted according to the National Institute for Health and Clinical Excellence quality assessment tool.
RESULTS: A total of 8 articles meeting inclusion and exclusion criteria were identified, involving 323 patients with hyperpigmented scars treated with fat grafting. A significant difference in scar pigmentation was noted after treatment with fat grafting according to observers' ratings, with a SMD of - 1.09 [95% CI: - 1.32; - 0.85], p<0.01. The SMD for patient-reported scar pigmentation after treatment with fat grafting was - 0.99 [96% CI: - 1.31; - 0.66], p<0.01. Four studies provided objective measurements of melanin changes after fat grafting and revealed inconsistent findings compared to subjective observations.
CONCLUSIONS: Fat grafting shows promise in ameliorating hyperpigmented scars based on subjective assessments, but further corroborating evidence from objective measures is required.
LEVEL OF EVIDENCE IV: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
The researchers will deliver to each patient 10 kits for the analysis of the GIP and they will ask them to use them two times per week, for 5 weeks. Furthermore, the patients will test urine GIP in the event of symptoms/signs that they attribute to the accidental intake of gluten, within the same 5 weeks. Both gastrointestinal and extra-intestinal symptoms which the patients will attribute to the accidental intake of gluten, will be considered.
Proposed research sets to collect pilot data to examine how the proposed neural, psychophysiological and subjective markers measured before, during, and after treatment change over the course of Prolonged Exposure (PE) therapy for posttraumatic stress disorder (PTSD). Fifty participants will be screened with the goal of obtaining 15 participants to complete the study. Participants will complete ten 60-minute sessions of PE. During each PE session, participants will be outfitted with a NINscan device to record psychophysiological measures including skin conductance, heart rate, and facial EMG, as well as neural measures of LPFC activity. Multimodal assessment batteries will be scheduled to take place at pre-treatment, mid-treatment (i.e., post session 5), post-treatment (i.e., post-session 10), and at 1-month follow-up. These sessions will include a battery of self-report measures, clinician-administered diagnostic interviews, and script-driven imagery (SDI) procedures with physiologic and neural recordings. The primary outcome measure will be PTSD symptom change on the CAPS-5 and the secondary outcome measures will be a) change in self-reported symptom severity, b) premature treatment dropout, and c) change in psychophysiological reactivity and LPFC activity during the SDI procedures. This proposed research will inform theoretical models of exposure therapy efficacy, with the goal of enhancing prolonged exposure therapy.
OBJECTIVE: Minimal change disease (MCD) is a common nephrotic syndrome that is usually steroid-sensitive and has high relapse rate. The aim of this study was to investigate the relationship between time to clinical remission and recurrence after the initial steroid therapy.
METHODS: Among 305 adult patients diagnosed with MCD via light and electron microscopy, sensitive to steroids, and hospitalized for nephrotic syndrome in the Department of Nephrology of the Affiliated Hospital of Guangdong Medical University in China, 88 were included in this retrospective cohort study. Cox regression analysis was performed with time to clinical remission and 24-hour urine protein quantification (24 hUTP), absolute basophil (BA) and basophil percentage (BA%) as independent variables. Independent variables with significant differences and the time to remission were used to construct a Cox regression model to exclude the influence of confounding factors. The receiver operating characteristic (ROC) curve was plotted according to the independent variable of time to clinical remission.
RESULTS: No significant differences were found between the relapse and non-relapse groups in terms of sex, age at onset, or prevalent hypertension. There were significant differences in time to clinical remission, 24 hUTP, BA and BA% between the relapse and non-relapse groups. The risk of recurrence was significantly higher in patients with clinical remission of 15-21, 22-28 and 29-56 days than in those who had clinical remission of 1-7 days. In addition, patients with clinical remission of >26.5 days had a significantly higher risk of recurrence than those in the other groups.
CONCLUSIONS: Overall, the time of clinical remission is a potential factor for predicting the recurrence of steroid-sensitive MCD in adults.
Described are caffeine-based delivery vehicles. A first delivery vehicle is a malleable strip that dissolves in an oral cavity. Buccal absorption provides a prompt mental and physical stimulation for the user. The strips are formulated with beneficial ingredients comprising caffeine, taurine and/or nitric oxide. The strips are contained in a small crush-proof package for convenience. A second delivery vehicle is a gel. The gel provides a prompt and sustained effect. The sustained effect based on gastric absorption of ingested gel that does not absorb through contact with a user's oral cavity. A high viscosity of the gel enhances the buccal absorption. Like the strips, the gel is formulated with beneficial ingredients comprising caffeine, taurine and/or nitric oxide. The gel is contained in packages having an integrated, re-sealable straw.
PRCIS: Phacoemulsification with goniosynechialysis (phaco-GSL) demonstrates promise in safely and efficiently managing advanced primary angle closure glaucoma (PACG) cases with tunnel vision or limited temporal visual field. However, caution is advised for patients with only one functioning eye or high visual expectations.
OBJECTIVE: To assess the efficacy and safety of phaco-GSL in patients with end-stage PACG exhibiting tubular vision or temporal field island.
PATIENTS AND METHODS: This retrospective study evaluated 68 patients (74 eyes) diagnosed with advanced PACG and exhibiting either tubular vision or temporal field island. All patients underwent phaco-GSL and were monitored for at least 1 month postoperatively. The study analyzed changes in visual acuity (VA), intraocular pressure (IOP), medication use for antiglaucoma, and postoperative complications.
RESULTS: The mean follow-up time was 9.11 ± 10.49 months. The mean preoperative visual field deviation and VA were -28.01 ± 3.30 dB and 0.36 ± 0.37 log minimum angle of resolution unit, respectively. Postoperatively, the VA for over half (54.1%) of the eyes increased, 29.7% remained unchanged, and 16.2% worsened. The final IOP decreased significantly from 24.65 ± 8.61 to 14.81 ± 3.54 mm Hg. Glaucoma medication use also reduced from 1.46 ± 1.43 to 0.88 ± 1.18. The success rate was 48.6% for complete and 89.2% for qualified. IOP spikes (27.0%) and wipe-out (8.1%) were the most common postoperative complications. Vision recovered gradually in 5 of 6 wipe-out patients. One eye (1.4%) developed permanent vision loss with VA decreasing to hand motion.
CONCLUSION: Phaco-GSL appears safe and effective in treating advanced PACG cases with tubular vision or temporal field island. However, caution is warranted when considering this treatment option for patients at high wipe-out risk or those with high expectations for visual outcomes.
In this group patient will be treated with standard treatment protocol. This group will receive therapy session for 1 hour, three sessions in a week and for 6 weeks, total sessions will be 18. Group A will receive soft tissue massage therapy for 5 mins and the task specific training interventions include bicycle training for 10 mins. After that aerobic exercises includes and finally some of progressive resistive exercises will involve in it.
PURPOSE OF REVIEW: This review assesses the effectiveness and safety of light therapy, particularly green light therapy, as an emerging non-pharmacological treatment for chronic migraine (CM). It aims to highlight alternative or complementary approaches to traditional pharmacological remedies, focusing the need for diverse treatment options.
RECENT FINDINGS: Despite sensitivity to light being a defining feature of migraine, light therapy has shown promising signs in providing substantial symptom relief. Studies have provided insights into green light therapy's role in managing CM. These studies consistently demonstrate its efficacy in reducing the frequency, severity, and symptoms of migraines. Additional benefits observed include improvements in sleep quality and reductions in anxiety. Importantly, green light therapy has been associated with minimal side effects, indicating its potential as a suitable option for migraine sufferers. In addition to green light, other forms of light therapy, such as infrared polarized light, low-level laser therapy (LLLT), and intravascular irradiation of blood (ILIB), are also being explored with potential therapeutic effects. Light therapies, especially green light therapy, are recognized as promising, safe, and non-pharmacological interventions for treating CM. They have been shown to be effective in decreasing headache frequency and enhancing the overall quality of life. However, current studies, often limited by small sample sizes, prompt more extensive clinical trials to better understand the full impact of light therapies. The exploration of other light-based treatments, such as LLLT and ILIB, warrants further research to broaden the scope of effective migraine management strategies.
Subjects will participate in supervised sessions (clinic-based) of exercise followed by a home exercise program 2 times per week during 3 months. Each exercise session will last about 60 minutes. Treatment sessions will utilize a pragmatic approach and will include the exercises designed to increase muscular strength, low impact cardiovascular exercise, range of movement, and activity for daily living skills.
Antimicrobial foams and methods of making same. The antimicrobial foams can include a polymeric foam having a wet-out time of at least 250 sec; and a coating comprising an antimicrobial material. The antimicrobial material can include a quaternary ammonium compound, and the antimicrobial material can be covalently bound to the foam. The antimicrobial foam can include at least 0.25 parts by weight of quarternary ammonium compound per 100 parts by dry weight of the foam. The method can include providing the polymeric foam and an antimicrobial material comprising a quaternary ammonium precursor. The method can further include combining the foam and the quaternary ammonium precursor to form a combination; and heating the combination to a temperature of at least 40 °C to form an antimicrobial foam comprising a quaternary ammonium compound covalently bound to the foam.
Conventional treatments for ventriculitis, including: external ventricular drainage or lumbar cistern drainage for continuous drainage, systemic and intrathecal antibiotics along with other supportive care. The treatment plan, including the type, dosage, and duration of antibiotics, follows guidelines "2017 Infectious Diseases Society of America's Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis".
The present invention relates to a pIL-12 gene adjuvant for pig vaccine and a preparing method thereof, wherein pIL-12 comprises encoding genes p35 and p40 of two subunits. The total RNA is extracted from swine peripheral blood mononuclear cells (PBMC) activated by LPS. Encoding genes p35 and p40 of two subunits of pIL-12 are amplified with a RT-PCR method. Then p35 gene and p40 gene are respectively sub-cloned to prokaryotic expression vectors pET30c and pET30b. The pIL-12 gene is cloned. The IL-12 is an effective adjuvant for actuating protective cellular immunity and has important function in regulating non-specific immunity and specific immunity of body. The regulating mode is mainly finished through simulating NK cell and cytotoxic lymphocyte. The IL-12 can regulate the direction of immunoreaction and provides theoretical principle for the application of cytokine on the inactivated vaccine.